
Arbutus Biopharma ( ($ABUS) ) just unveiled an update. On November 12, 2026, Arbutus Biopharma posted an updated corporate presentation outlining its cHBV programs and reporting cash and cash equivalents
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ABUS | Arbutus Biopharma | 4.11 | -0.41 | -8.99% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.11 | -8.99% |

Arbutus Biopharma ( ($ABUS) ) just unveiled an update. On November 12, 2026, Arbutus Biopharma posted an updated corporate presentation outlining its cHBV programs and reporting cash and cash equivalents

Arbutus Biopharma (ABUS) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Arbutus Biopharma to post earnings of -$0.02 per share. Revenue expectations

The latest announcement is out from Arbutus Biopharma ( ($ABUS) ). On October 22, 2026, Arbutus Biopharma announced that the U.S. Food and Drug Administration lifted the clinical hold on

Arbutus Biopharma (ABUS) announced that the company was notified by the FDA that the clinical hold on the investigational new drug, or IND, application for AB-101 has been removed and

Latest data shows the largest indicative borrow rate increases among liquid option names include: PDS Biotechnology Corp (PDSB) 10.40% +6.80, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.22% +3.70,

Latest data shows the largest indicative borrow rate increases among liquid option names include: Arbutus Biopharma (ABUS) 36.19% +33.17, Biomea Fusion (BMEA) 4.23% +2.82, Campbell Soup (CPB) 15.28% +1.36, Aries

An update from Arbutus Biopharma ( ($ABUS) ) is now available. Arbutus Biopharma has reported preliminary results of its US$230 million modified Dutch auction tender offer to repurchase common shares.

Arbutus Biopharma ( ($ABUS) ) has provided an update. Arbutus Biopharma has launched a modified Dutch auction tender offer to repurchase and cancel up to US$230 million of its common

Arbutus Biopharma (ABUS) announced the commencement of a modified Dutch Auction tender offer to purchase for cancellation up to $230M in value of its common shares at a price of

The major averages were broadly higher near noon, potentially ending the week on a high note as investors attempt to shake off a yield-driven selloff. Long-dated Treasury yields surged this
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Dec 11, 2025 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $620.84M | $-0.02 | $1.00M | 0.51 | 3.57 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.